(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

VYVGART HYTRULO faces a new FDA safety signal related to CIDP, but I believe this is not a major concern for the franchise. The main issue is the transition from IVIg to VYVGART HYTRULO in real-world ...

Argenx SE (NASDAQ:ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo ...